Clinical trials: Androgens
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent).
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03371719
- Testing
- Apalutamide, External Beam Radiation Therapy
- Where
- 360 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- NRG Oncology
Lacrimal Apparatus Disease, Salivary Gland Disease
DHEA Treatment for Sjogren's Syndrome
This study will evaluate the effectiveness of the male hormone dehydroepiandrosterone (DHEA) in treating Sjogren's syndrome. This autoimmune disorder, in which the immune system attacks the salivary glands and tear glands…
- Conditions
- Lacrimal Apparatus Disease, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
- Trial name
- NCT00001598
- Testing
- Dehydroepiandrosterone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Polycystic Ovary Syndrome (PCOS)
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Introduction : Androgens play a vital role in the female reproductive system, influencing ovarian follicular development, oocyte quality, and ovarian responsiveness to controlled ovarian stimulation.
- Trial name
- NCT07916909
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Hypoactive Sexual Desire Disfunction
Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder (HSDD) is the most prevalent female sexual dysfunction in society and is strongly linked to the quality of life of women.
- Trial name
- NCT01971099
- Testing
- tribulus terrestris
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- Federal University of Minas Gerais
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Metastatic Hormone-Sensitive Prostate Cance
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise…
- Trial name
- GUARD-QUANTUM (NCT07717099)
- Testing
- Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT)
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic
Prostate Cancer, Metabolic Syndrome
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A.
- Conditions
- Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity
- Trial name
- NCT05802121
- Testing
- Apple Cider Vinegar
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
Prostate Cancer
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003084
- Testing
- Doxorubicin Hydrochloride, Estramustine phosphate sodium, Etoposide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Non-metastatic Castration-resistant Prostate Cancer
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that…
- Trial name
- NCT05348876
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 25 sites in India
- Volunteers
- 50 people
- Sponsor
- Bayer
Polycystic Ovary Syndrome
Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
The mechanism for increased androgen production in women with polycystic ovary syndrome (PCOS) is not well understood. Excess androgen production by the ovary is stimulated by increased pituitary luteinizing hormone (LH)…
- Trial name
- NCT00747617
- Testing
- recombinant human chorionic gonadotropin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Cancer
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00031889
- Testing
- Exemestane, Exemestane+bicalutamide
- Where
- 12 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer Metastatic Disease
Role of Race in Nutritional Approach in Men on ADT
There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributing to an increase in cardiovascular risk factors (CVRFs) and…
- Trial name
- NCT06682390
- Testing
- Hypocaloric anti-inflammatory diet
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, Los Angeles
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
Primary Objective: To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m^2) plus prednisone (Arm A) versus either enzalutamide at 160…
- Trial name
- PRIMCAB (NCT02379390)
- Testing
- Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate
- Where
- 24 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Sanofi
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04754425
- Testing
- Biopsy, Biospecimen Collection, Erdafitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer
This is a single-arm, open label phase II trial of the investigational agent, Ara-C (cytarabine), in patients diagnosed with hormone refractory prostate cancer whose disease has progressed on or deemed not suitable for standard…
- Trial name
- SLAP (NCT00480090)
- Testing
- Cytarabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Vasomotor Symptoms, Prostate Cancer
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
- Trial name
- NCT07568236
- Testing
- Fezolinetant
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
- Trial name
- ARMOR3-SV (NCT02438007)
- Testing
- Galeterone, Enzalutamide
- Where
- 117 sites in United States, Australia and 6 more
- Volunteers
- 953 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Pilonidal Disease, Pilonidal Disease of Natal Cleft
Topical Anti-Androgens in Pilonidal Sinus Disease
The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft.
- Conditions
- Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
- Trial name
- NCT06286397
- Testing
- 1% Clascoterone, Vehicle Cream
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.